Hims & Hers Health’s (HIMS) “Hold” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reaffirmed their hold rating on shares of Hims & Hers Health (NYSE:HIMS) in a report issued on Tuesday, Marketbeat.com reports. The firm currently has a $15.00 price objective on the stock, down from their previous price objective of $17.00.

Several other research analysts have also recently weighed in on the company. Tigress Financial boosted their price objective on Hims & Hers Health from $14.00 to $15.00 and gave the stock a buy rating in a research report on Friday, January 5th. Leerink Partnrs reissued a market perform rating on shares of Hims & Hers Health in a research report on Monday, February 26th. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a research report on Wednesday, April 10th. They issued a buy rating and a $20.00 price objective on the stock. SVB Leerink assumed coverage on Hims & Hers Health in a research report on Monday, February 26th. They issued a market perform rating and a $10.00 price objective on the stock. Finally, Truist Financial boosted their price objective on Hims & Hers Health from $10.00 to $13.00 and gave the stock a hold rating in a research report on Tuesday, February 27th. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat, Hims & Hers Health currently has a consensus rating of Moderate Buy and an average price target of $14.85.

Hims & Hers Health Trading Down 0.6 %

Shares of Hims & Hers Health stock opened at $12.34 on Tuesday. The stock has a fifty day simple moving average of $13.47 and a 200 day simple moving average of $9.80. Hims & Hers Health has a 12-month low of $5.65 and a 12-month high of $17.16.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.03. Hims & Hers Health had a negative return on equity of 7.21% and a negative net margin of 2.70%. The business had revenue of $246.60 million during the quarter, compared to the consensus estimate of $245.84 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. Hims & Hers Health’s revenue was up 47.4% compared to the same quarter last year. On average, research analysts anticipate that Hims & Hers Health will post 0.1 earnings per share for the current year.

Insider Activity

In related news, CEO Andrew Dudum sold 127,688 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $9.08, for a total transaction of $1,159,407.04. Following the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at approximately $469,009.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, CEO Andrew Dudum sold 127,688 shares of the stock in a transaction dated Thursday, January 25th. The stock was sold at an average price of $9.08, for a total transaction of $1,159,407.04. Following the sale, the chief executive officer now owns 51,653 shares of the company’s stock, valued at approximately $469,009.24. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,503 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $13.95, for a total value of $34,916.85. Following the sale, the insider now directly owns 164,363 shares in the company, valued at approximately $2,292,863.85. The disclosure for this sale can be found here. Insiders have sold 675,838 shares of company stock valued at $8,487,125 in the last 90 days. Insiders own 31.63% of the company’s stock.

Hedge Funds Weigh In On Hims & Hers Health

A number of institutional investors have recently added to or reduced their stakes in HIMS. Swiss National Bank increased its stake in Hims & Hers Health by 7.9% in the 1st quarter. Swiss National Bank now owns 185,000 shares of the company’s stock worth $986,000 after acquiring an additional 13,500 shares during the last quarter. Citigroup Inc. increased its stake in Hims & Hers Health by 249.9% in the 1st quarter. Citigroup Inc. now owns 34,718 shares of the company’s stock worth $185,000 after acquiring an additional 24,796 shares during the last quarter. Ergoteles LLC bought a new position in Hims & Hers Health in the 1st quarter worth about $949,000. Charles Schwab Investment Management Inc. increased its stake in Hims & Hers Health by 2.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 616,214 shares of the company’s stock worth $3,285,000 after acquiring an additional 14,990 shares during the last quarter. Finally, Northern Trust Corp increased its stake in Hims & Hers Health by 1.3% in the 1st quarter. Northern Trust Corp now owns 253,307 shares of the company’s stock worth $1,350,000 after acquiring an additional 3,226 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.